BioAdaptives

BioAdaptives FCF/Net Income

The Free Cash Flow to Net Income Ratio of BioAdaptives (BDPT) as of Nov 1, 2026 is 34.28 %. In the previous year, Free Cash Flow to Net Income Ratio was 27.76 % — a change of 23.50% (higher).

FCF/Net Income

34.28 %

YoY

23.50%

Last updated:

Free Cash Flow to Net Income Ratio of BioAdaptives is 2025 34.28 % . Free Cash Flow to Net Income Ratio of BioAdaptives was 2024 27.76 % . It decreases by 23.50% higher compared to the previous year.

The BioAdaptives FCF/Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Net Income
Date
FCF/Net Income
Jan 1, 2018
28.59 USD
Jan 1, 2019
38.36 USD
Jan 1, 2020
9.92 USD
Jan 1, 2021
15.11 USD
Jan 1, 2022
25.36 USD
Jan 1, 2023
31.43 USD
Jan 1, 2024
27.76 USD
Jan 1, 2025
34.28 USD
The BioAdaptives FCF/Net Income history
YEARFCF/Net IncomeYoY
34.28 %+23.50%
27.76 %-11.69%
31.43 %+23.91%
25.36 %+67.86%
15.11 %+52.32%
9.92 %-74.14%
38.36 %+34.19%
28.59 %+3,208.81%
0.86 %-126.57%
-3.25 %-10,373.75%
0.03 %-98.65%
2.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioAdaptives Stock analysis

What does BioAdaptives do? BioAdaptives, Inc. generates revenue through the sale of health and wellness products including dietary supplements, specialty food items, and devices that optimize bioelectromagnetic availability. The company markets PrimiCell and PrimiLive under a product agreement with Ferris Holding, Inc., targeting consumers seeking cognitive enhancement, fatigue reduction, and anti-aging solutions. PrimiTrim serves the weight control segment, while Equine Regen and Equine Regen Plus are in advanced testing for veterinary use. The firm also develops a dog product, expanding its wellness offerings across human and animal health markets. Ferris Holding, Inc. provides the intellectual property and products that BioAdaptives markets, including PrimiCell and PrimiLive, which are positioned for cognition, focus, and emotional wellness. The company's advanced-stage products Equine Regen and Equine Regen Plus cater to the veterinary segment, with PrimiTrim addressing weight management needs. BioAdaptives' product portfolio spans nutraceuticals, devices, and specialty foods designed to improve physical and emotional wellness across multiple consumer segments. BioAdaptives focuses on selling devices and nutraceuticals that target cognitive performance, fatigue reduction, and anti-aging, with PrimiCell and PrimiLive as key products under the Ferris agreement. The company's weight control solution PrimiTrim appeals to consumers seeking wellness through diet, while Equine Regen and Equine Regen Plus target animal health providers. The firm's development of a dog product further diversifies its offerings in the wellness market. BioAdaptives is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioAdaptives stock

Free Cash Flow to Net Income Ratio of BioAdaptives is 34.28 % in 2025.

Free Cash Flow to Net Income Ratio of BioAdaptives changed from 27.76 % to 34.28 %, representing a 23.50% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Net Income Ratio BioAdaptives since 2006 – with annual values, charts, and detailed analysis.

The FCF/Net Income ratio measures cash flow quality. Ratios consistently above 100% suggest high-quality earnings with strong cash backing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Net Income Ratio's BioAdaptives with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow to Net Income Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow to Net Income Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — BioAdaptives

All Key Metrics — BioAdaptives